Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 20, 2018 in Colorectal cancer | 0 comments

In a nutshell

This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects.

Some background

Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell death. Recent studies showed that this agent combined with irinotecan as third line therapy was associated with improved outcomes in metastatic (spread to other parts of the body) colorectal cancer.

Another study showed that 60 and 30 minute injections of panitumumab alone had similar effects on the patients without increased side effects. Although 15-minute injections would enhance patient convenience, the effectiveness and toxicity of this treatment is not clear.

Methods & findings

The objective of this study was to evaluate the effectiveness and safety of 15-minute injections of panitumumab to treat advanced colorectal cancer.

43 patients with metastatic colorectal cancer were included. All patients received chemotherapy twice a week, consisting of panitumumab, irinotecan, 5-HT3 and dexamethasone. The initial panitumumab injection was given over 60 minutes, followed by a 30-minute injection and then 15-minute injections. Treatment continued until disease progression or toxicity. After an average follow-up period of 16.8 months, 32 patients had stopped treatment due to progression or toxicity.

The total cancer response rate was 37.2%. The average progression-free survival (time from treatment to cancer progression) was 5.8 months and overall survival (time from treatment until death from any cause) was 13.6 months. 9 patients did not reach the 15-minute injection mostly because of disease progression.

The most common negative effects were anorexia (12%; lack or loss of appetite for food), leukopenia and neutropenia (9%; a reduction in the number of white cells in the blood). No injection-related reactions were observed.

The bottom line

This study showed that 15-minute injections of panitumumab was well tolerated without compromising effectiveness or toxicity.

Published By :

Clinical Colorectal Cancer

Date :

Mar 01, 2018

Original Title :

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).

click here to get personalized updates